{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:59:16Z","timestamp":1761469156825,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.transci.2021.103159","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T21:57:51Z","timestamp":1621461471000},"page":"103159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-0119","authenticated-orcid":false,"given":"Ahmet","family":"Sar\u0131c\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-4555","authenticated-orcid":false,"given":"\u00d6mer Faruk","family":"Bah\u00e7ecio\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3179-1899","authenticated-orcid":false,"given":"Selim","family":"G\u00f6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rfan","family":"Kuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soykan","family":"Bi\u00e7im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lhami","family":"Berber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emin","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"CA Cancer","author":"Siegel","key":"10.1016\/j.transci.2021.103159_bib0005"},{"key":"10.1016\/j.transci.2021.103159_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/bbmt.2003.50002","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review","volume":"9","author":"Hahn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0015","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2021.103159_bib0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells\u2014definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0025","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2021.103159_bib0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0035","first-page":"621","article-title":"Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study","volume":"91","author":"de la Rubia","year":"2006","journal-title":"haematologica"},{"key":"10.1016\/j.transci.2021.103159_bib0040","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3109\/10428194.2015.1102240","article-title":"Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF","volume":"57","author":"Jang","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2021.103159_bib0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bmt.1703855","article-title":"Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria","volume":"31","author":"Maiolino","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clml.2018.12.010","article-title":"Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era","volume":"19","author":"Arora","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.transci.2021.103159_bib0055","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","article-title":"A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients","volume":"27","author":"Fitoussi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0060","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41409-018-0152-2","article-title":"Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma","volume":"53","author":"Chua","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jca.21283","article-title":"Hematopoietic progenitor cell mobilization using low\u2010dose cyclophosphamide and granulocyte colony\u2010stimulating factor for multiple myeloma","volume":"28","author":"Shimura","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2021.103159_bib0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","article-title":"Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone","volume":"20","author":"Alegre","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0080","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","article-title":"Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma","volume":"14","author":"Mark","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bmt.2010.63","article-title":"Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen","volume":"46","author":"Nazha","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","article-title":"Cyclophosphamide\u2010based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"30","author":"Tuchman","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2021.103159_bib0095","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2015.190","article-title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","volume":"50","author":"Uy","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2021.103159_bib0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jca.21421","article-title":"Cyclophosphamide plus granulocyte\u2010colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma","volume":"31","author":"Lin","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2021.103159_bib0105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00277-016-2897-2","article-title":"Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone","volume":"96","author":"Benyamini","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2021.103159_bib0110","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.transci.2021.103159_bib0115","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","article-title":"Factors influencing collection of peripheral blood progenitor cells following high\u2010dose cyclophosphamide and granulocyte colony\u2010stimulating factor in patients with multiple myeloma","volume":"98","author":"Goldschmidt","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2021.103159_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2019.06.023","article-title":"Predictive factors for stem cell mobilization failure in multiple myeloma patients: a single center experience","volume":"59","author":"Goker","year":"2020","journal-title":"Transfus Apher Sci"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:53:54Z","timestamp":1761468834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050221001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1473050221001257"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2021.103159","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2021.103159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103159"}}